{"nctId":"NCT01721746","briefTitle":"A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)","startDateStruct":{"date":"2012-12-21","type":"ACTUAL"},"conditions":["Unresectable or Metastatic Melanoma"],"count":405,"armGroups":[{"label":"BMS-936558 3 mg/kg (IV)","type":"EXPERIMENTAL","interventionNames":["Biological: BMS-936558"]},{"label":"Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dacarbazine","Drug: Carboplatin","Drug: Paclitaxel"]}],"interventions":[{"name":"BMS-936558","otherNames":[]},{"name":"Dacarbazine","otherNames":["DTIC-Dome","DTIC"]},{"name":"Carboplatin","otherNames":["Paraplatin","CBDCA"]},{"name":"Paclitaxel","otherNames":["Onxol"]}],"eligibilityModule":{"eligibilityCriteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Men \\& women â‰¥ 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1\n* Histologically confirmed Stage III (unresectable)/Stage IV melanoma\n* Measurable disease by computed tomography (CT)/magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\n* Objective evidence of disease progression (clinical or radiological) during or after at least 1 (V600 Wildtype) or at least 2 (V600 mutation positive) prior treatment regimens\n* Pre-treatment fresh core, excision or punch tumor biopsy\n* Archival Formalin-fixed paraffin-embedded (FFPE) tumor material if available\n\nExclusion Criteria:\n\n* Any treatment in a BMS-936558 (Nivolumab) trial\n* Subjects with condition requiring systemic treatment with either corticosteroids (\\> 10mg daily prednisone/equivalent) or other immunosuppressive medications within 14 days of study drug administration\n* Active, known or suspected autoimmune disease\n* Unknown BRAF status\n* Active brain metastasis or leptomeningeal metastasis\n* Ocular melanoma\n* Prior therapy with anti programmed death-1 (anti-PD-1), anti programmed death-ligand 1 (anti-PD-L1) or anti-programmed death-ligand 2 (anti-PD-L2)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Objective Response Rate (ORR)","description":"Objective response rate (ORR) per Independent Review Committee (IRC) is defined as the number of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) divided by the number of randomized participants using RECIST 1.1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival (OS)","description":"Overall Survival (OS) was defined the time between the date of randomization to the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive. Unit of measure (months) is the median survival time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.74","spread":null},{"groupId":"OG001","value":"14.39","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by the Independent Review Committee (IRC) using RECIST 1.1, or death due to any cause, whichever occurs first. Participants who died without a reported progression were considered to have progressed on the date of their death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment before subsequent anti-cancer therapy. Unit of measure (months) is the median survival time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.12","spread":null},{"groupId":"OG001","value":"3.65","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) by Baseline PD-L1 Expression","description":"Objective Response Rate (ORR) is defined as the number of participants with a Best Overall Response (BOR) of complete response (CR) or partial response (PR) divided by number of randomized participants. PD-L1 expression evaluated for ORR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null},{"groupId":"OG001","value":"12.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) by PD-L1 Positive","description":"Overall Survival (OS) by PD-L1 expression was defined the time between the date of randomization to the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.44","spread":null},{"groupId":"OG001","value":"16.72","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) by PD-L1 Negative","description":"Overall Survival (OS) by PD-L1 expression was defined the time between the date of randomization to the date of death. For participants without documentation of death, OS was censored on the last date the participant was known to be alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.14","spread":null},{"groupId":"OG001","value":"11.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Health-related Quality of Life (HRQoL)","description":"Health-related Quality of Life (HRQoL) was assessed with the EORTC QLQ-C30 questionnaire, which is the most commonly used quality-of-life instrument in oncology trials. The instrument's 30 items were divided among 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a global health/quality of life scale. Raw scores for the EORTC QLQ-C30 were transformed to a 0-100 metric.\n\nHigher scores for all functional scales and Global Health Status=better HRQoL Increase from baseline indicates improvement in HRQoL. Lower scores for symptom scales=better HRQoL Decline from baseline for symptom scales =improvement in symptoms compared to baseline.\n\nA 10 point difference on a 100 point scale between treatments was considered clinically significant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.97","spread":"20.49"},{"groupId":"OG001","value":"-12.73","spread":"21.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.66","spread":"16.05"},{"groupId":"OG001","value":"-7.14","spread":"16.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.94","spread":"31.13"},{"groupId":"OG001","value":"-15.91","spread":"29.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.80","spread":"25.56"},{"groupId":"OG001","value":"-8.33","spread":"21.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.09","spread":"21.59"},{"groupId":"OG001","value":"-15.48","spread":"24.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.94","spread":"19.15"},{"groupId":"OG001","value":"-5.36","spread":"25.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.58","spread":"16.79"},{"groupId":"OG001","value":"-7.94","spread":"17.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.49","spread":"15.43"},{"groupId":"OG001","value":"-1.19","spread":"13.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.66","spread":"29.45"},{"groupId":"OG001","value":"-18.25","spread":"26.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.61","spread":"29.52"},{"groupId":"OG001","value":"-4.17","spread":"24.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.23","spread":"22.44"},{"groupId":"OG001","value":"-10.71","spread":"17.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.61","spread":"18.53"},{"groupId":"OG001","value":"-3.27","spread":"12.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.06","spread":"27.96"},{"groupId":"OG001","value":"16.67","spread":"24.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.91","spread":"22.20"},{"groupId":"OG001","value":"7.14","spread":"24.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.46","spread":"32.26"},{"groupId":"OG001","value":"0.00","spread":"30.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.84","spread":"25.50"},{"groupId":"OG001","value":"0.00","spread":"30.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.93","spread":"28.79"},{"groupId":"OG001","value":"13.64","spread":"24.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.91","spread":"30.49"},{"groupId":"OG001","value":"2.38","spread":"22.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.36","spread":"28.93"},{"groupId":"OG001","value":"0.00","spread":"23.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"22.48"},{"groupId":"OG001","value":"-2.38","spread":"29.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"19.86"},{"groupId":"OG001","value":"6.35","spread":"22.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":"20.88"},{"groupId":"OG001","value":"1.19","spread":"16.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.73","spread":"25.87"},{"groupId":"OG001","value":"4.76","spread":"39.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.08","spread":"22.56"},{"groupId":"OG001","value":"-2.38","spread":"28.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.95","spread":"23.78"},{"groupId":"OG001","value":"15.66","spread":"28.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.84","spread":"22.55"},{"groupId":"OG001","value":"7.14","spread":"21.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":"17.19"},{"groupId":"OG001","value":"10.61","spread":"25.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"15.39"},{"groupId":"OG001","value":"2.98","spread":"18.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.06","spread":"31.17"},{"groupId":"OG001","value":"6.82","spread":"25.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.38","spread":"24.84"},{"groupId":"OG001","value":"-1.79","spread":"14.59"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":191,"n":268},"commonTop":["Fatigue","Nausea","Diarrhoea","Arthralgia","Anaemia"]}}}